Krilogy Financial LLC Acquires Shares of 4,276 Eli Lilly and Company $LLY

Krilogy Financial LLC bought a new position in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,276 shares of the company’s stock, valued at approximately $3,263,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Madison Asset Management LLC boosted its holdings in Eli Lilly and Company by 5.7% in the 3rd quarter. Madison Asset Management LLC now owns 58,856 shares of the company’s stock valued at $44,907,000 after purchasing an additional 3,168 shares in the last quarter. Westbourne Investments Inc. lifted its holdings in shares of Eli Lilly and Company by 70.5% in the 3rd quarter. Westbourne Investments Inc. now owns 3,674 shares of the company’s stock valued at $2,803,000 after buying an additional 1,519 shares during the period. ABC Arbitrage SA purchased a new stake in shares of Eli Lilly and Company in the third quarter valued at approximately $1,258,000. Signet Investment Advisory Group Inc. boosted its stake in shares of Eli Lilly and Company by 9.6% in the third quarter. Signet Investment Advisory Group Inc. now owns 4,439 shares of the company’s stock valued at $3,387,000 after buying an additional 387 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its position in Eli Lilly and Company by 3.8% in the third quarter. Stratos Wealth Partners LTD. now owns 32,310 shares of the company’s stock worth $24,653,000 after acquiring an additional 1,183 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on LLY. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st. CICC Research boosted their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Zacks Research lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. TD Cowen lifted their price target on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Finally, National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a research note on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,217.71.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,025.06 on Wednesday. The company has a market cap of $969.08 billion, a P/E ratio of 44.66, a P/E/G ratio of 0.90 and a beta of 0.39. The business has a fifty day simple moving average of $1,051.59 and a 200-day simple moving average of $902.97. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The firm’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period last year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 30.15%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly agreed to buy Orna Therapeutics for up to $2.4 billion, gaining in‑vivo CAR‑T and circular RNA capabilities that diversify Lilly’s heavy GLP‑1 exposure and bolster long‑term growth prospects. Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion
• Positive Sentiment: Multiple outlets note the Orna deal as strategic entry into next‑generation cell therapy and genetic medicine, which investors view as high‑value pipeline expansion beyond GLP‑1s. LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal
• Positive Sentiment: Fisher Asset Management boosted its Eli Lilly stake by ~153,000 shares, a vote of confidence from a high‑profile investor that can support near‑term buying. Fisher Asset Management Boosts Eli Lilly Stake by 153K Shares
• Positive Sentiment: Lilly advanced two clinical programs: solbinsiran moving forward in high‑risk cholesterol studies and eloralintide entering Phase 3 for obesity — both reinforce future revenue diversification beyond GLP‑1s. Eli Lilly’s Solbinsiran Trial Advances in High-Risk Cholesterol Market
• Positive Sentiment: Deutsche Bank raised its price target on LLY, signaling bullish analyst sentiment and adding to the momentum. Read More
• Neutral Sentiment: Lilly announced an expanded strategic collaboration with Innovent (multi‑billion opportunity) and a partnership with gene‑editing start‑up Seamless — both widen R&D reach but carry usual execution and milestone risk. Eli Lilly Enters $8.5 Billion Strategic Collaboration with Innovent Biologics and Acquires Orna Therapeutics
• Negative Sentiment: Analysts and media continue to flag concentration risk: GLP‑1 drugs still account for a large share of recent revenue, leaving the company exposed if market dynamics shift — valuation (P/E ~45) already prices high growth. Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.